Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma

Clinical and Experimental Metastasis

Volumn 17, Issue 1, 1999, Pages 19-25

  Matar, Pablo ^a   Rozados, Viviana R ^a   Binda, M Mercedes ^b   Roggero, Eduardo A ^a   Bonfil, R Daniel ^b   Scharovsky, O Graciela ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Cell attachment; Invasiveness; Lovastatin; Lymphoma metastasis

Indexed keywords

ANTIMETASTATIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIGEL; METALLOPROTEINASE; MEVINOLIN; PROTEIN P21;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CELL ADHESION; CELL MOTILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; LYMPHOMA CELL LINE; MALE; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRENYLATION; RAT; TUMOR GROWTH;

EID: 84988281451     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026445024899     Document Type: Article

References (56)

1. 1 to multiple cell cycles by Lovastatin. Cancer Res 1991; 51: 3602-9.
2. 1 phase blocks. Cell Growth Differ 1993; 4: 421-30.
3. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density Lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978; 52: 1099-114.
4. Siperstein MD, Fagan VM. Deletion of the cholesterol negative feedback system in liver tumors. Cancer Res 1964; 24: 1108-15.
5. Chen HW, Kandutsch AA, Heiniger HJ. The role of cholesterol in malignancy. Prog Exp Tumor Res 1978; 22: 275-316.
6. Kawata S, Takaishi K, Nagase T et al. Increase in the active form of 3-hydroxy-3-methylgutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990; 50: 3270-3.
7. Harwood HJ, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leucocyte-3-hydroxy-3-methylgutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 1992; 32: 1327-52.
8. Feingold KR, Wiley MH, Moser AH, Siperstein MD. Altered activation state of 3-hydroxy-3-methylgutaryl coenzyme A reductase in liver tumors. Arch Biochem Biophys 1983; 226: 231-41.
9. Maltese WA, Defendini R, Green RA et al. Suppression of murine neuroblastoma growth in vivo by mevilonin a competitive inhibitor of 3-hydroxy-3-methylgutaryl CoA reductase. J Clin Invest 1985; 76: 1748-54.
10. Quesney-Hueneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979; 76: 5056-60.
11. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature (Lond.) 1990; 343: 425-30.
12. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199: 1209-15.
13. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to Ras function and cancer intervention? Cell Growth Differ 1992; 3: 461-9.
14. Wolda SL, Glomset JA. Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem 1988; 263: 5997-6000.
15. 21ras C-terminus is required for transformation and membrane association. Nature 1984; 310: 583-6.
16. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991; 88: 3628-32.
17. Wedje J, Blegen H, Larsson O. Requirements for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res 1992; 12: 317-24.
18. Castellano F, Bruscalupi G, Columba S et al. Characterization of the response of growth and differentiation to lipoproteins and agents affecting cholesterol metabolism in murine neuroblastoma cells. Int J Dev Neurosci 1994; 12: 77-84.
19. Sumi S, Beauchamp RD, Townsend CM Jr. et al. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 1994; 9: 657-61.
20. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. Leukemia 1994; 8: 274-80.
21. Morris TJ, Palm SL, Furcht LL, Buchwald H. Effect of Lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann Surg Oncol 1995; 2: 266-74.
22. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996; 66: 710-6.
23. Carlberg M, Dricu A, Blegen H et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxi-3-methylglutaryl-coenzime A reductase and cell growth. J Biol Chem 1996; 271: 17453-62.
24. Sumi S, Beauchamp RD, Townsend CM Jr. et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992; 103: 982-9.
25. Soma MR, Baetta R, De Renzis MR et al. In vivo enhanced antitumor activity of Carmustine [N,N′-Bis(2-chloroethyl)-N-nitrosourea] by Simvastatin. Cancer Res 1995; 55: 597-602.
26. Bonfil RD, Reddel RR, Ura H et al. Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst 1989; 81: 587-94.
27. Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Critical Rev Oncogenesis 1993; 4: 95-114.
28. Jani JP, Specht S, Stemmler N et al. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 1993; 13: 314-24.
29. Matar P, Rozados V, Roggero E, Scharovsky OG. Actividad antimetastasica del Lovastatin, droga hipocolesterolemica. Medicina (Buenos Aires) 1995; 55: 522-3.
30. Calderari S, Font MT, Garrocq O et al. The inbred IIM/Fin stock. Rat News Lett 1991; 25: 28-9.
31. Celoria GC, Hinrichsen LI, Font MT. Tumor behavior of lymphoma TACB in rats resistant or susceptible to Sarcoma E-100. Com Biol 1986; 5: 73-83.
32. Bonfil RD, Vinyals A, Bustoabad OD et al. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 1994; 58: 233-9.
33. Bonfil RD, Russo DM, Schmilovich AJ. Exposure to Vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma. J Urol 1996; 156: 517-21.
34. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis. A quantitative and sensitive assay of the graft-vs-host reaction. J. Exp Med 1975; 141: 1084-100.
35. Broitman SA, Wilkinson J 4th, Cerda S, Branch SK. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic 'metastases' in vivo. Adv Exp Med Biol 1996; 401: 111-30.
36. Mehta N, Hordines J, Doerr RJ, Cohen SA. Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clin Exp Met 1998 (in press).
37. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130-8.
38. Rusciano D, Burger M. Why do cancer cells metastasize into particular organs? BioEssays 1992; 14: 185-94.
39. Nicolson GL. Cancer progression and growth: Relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993; 204: 171-80.
40. Aznavoorian S, Murphy AN, Steller-Stevenson WG and Liotta L. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368-83.
41. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613-8.
42. Bonfil RD, Medina PA, Gómez ED et al. Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clin Exp Metastasis 1992; 10: 211-20.
43. Duffy MJ. Urokinase plasminogen activator and malignancy. Fibrinolysis 1993; 7: 295-302.
44. Odekon LE, Sato Y, Rifkin DB, Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine cell migration independent of its proteolytic activity. J Cell Physiol 1992; 150: 258-63.
45. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
46. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
47. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996; 65: 717-22.
48. Tsujita Y, Kuroda M, Shimada Y et al. CS-514, a competitive inhibitor of 3-hydroxyl-3-methylglutaryl-coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986; 877: 50-60.
49. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. Br Med J 1989; 298: 920-4.
50. Kritz H, Zielinski C, Sinzinger H. Low cholesterol and cancer. J Clin Oncol 1996; 14: 3043-8.
51. Avall-Lundqvist EA, Peterson CO. Serum cholesterol and apolipoprotein B Levels may reflect disease activity in ovarian cancer patients. Acta Oncologica 1996; 35: 1007-9.
52. Tobert JA. Efficacy and long-term adverse effect pattern of Lovastatin. Am J Cardiol 1988; 62: 28J-34J.
53. Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 1990; 77: 58-65.
54. Thibault A, Samid D, Tompkins AC et al. Phase I study of Lovastatin an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
55. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
56. Cattley RC, Illingworth DR, Laws Amy, Pahor M. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 1479-80.